Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02922296 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glucose Metabolism in Sickle Cell Disease

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Aug 1, 2026 → Aug 1, 2028
See other at-risk trials from University of Illinois at Chicago

Record History

  1. Primary completion pushed from Aug 1, 2026 to Aug 1, 2028 Completion pushed from Aug 1, 2026 to Aug 1, 2029 · Secondary endpoints: details revised at 1 of 1 entry · Eligibility criteria expanded, about 4 words Show 3 more changesShow less
    • Completion pushed from Aug 1, 2026 to Aug 1, 2029
    • Secondary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria expanded, about 4 words
  2. Primary completion date: May 1, 2024 to Aug 1, 2026 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 1, 2025 to Aug 1, 2026 · Site details revisedv7 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 1, 2025 to Aug 1, 2026
    • Site details revised
  3. Trial status: Active, Not Recruiting to Recruiting Primary completion date: May 1, 2023 to May 1, 2024 · Completion date: Dec 1, 2023 to Dec 1, 2025 · Site details revisedv6 Show 3 more changesShow less
    • Primary completion date: May 1, 2023 to May 1, 2024
    • Completion date: Dec 1, 2023 to Dec 1, 2025
    • Site details revised
  4. Primary completion date: May 1, 2022 to May 1, 2023 Completion date: Dec 1, 2022 to Dec 1, 2023v5 Show 1 more changeShow less
    • Completion date: Dec 1, 2022 to Dec 1, 2023
  5. Primary completion date: May 1, 2020 to May 1, 2022 Trial status: Recruiting to Active, Not Recruiting · Completion date: Dec 1, 2020 to Dec 1, 2022 · Site details revisedv4 Show 3 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Completion date: Dec 1, 2020 to Dec 1, 2022
    • Site details revised
Show 2 earlier versionsHide 2 earlier versions
  1. Re-verified, no change to tracked fieldsv3
  2. Primary completion date: May 2017 to May 1, 2020 Completion date: Dec 2017 to Dec 1, 2020 · Start date: May 2015 to May 1, 2015v2 Show 2 more changesShow less
    • Completion date: Dec 2017 to Dec 1, 2020
    • Start date: May 2015 to May 1, 2015
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of the study is to better understand how the body handles sugars glucose and fats, such as cholesterol and triglycerides in sickle cell disease, and what puts certain persons at risk to develop diabetes. This understanding may help us to find new treatments to control blood sugar and prevent diabetes in people with and without sickle cell disease (SCD). In this research, DNA and RNA will be isolated from blood cells. DNA will be used to find genes that cause or protect from diabetes, high cholesterol and high triglyceride, and RNA will be used for studies designed to find out how genes are doing their job of eventually producing proteins.
Trial Details
NCT Number NCT02922296
Lead Sponsor University of Illinois at Chicago
Conditions Sickle Cell Disease, Diabetes Mellitus
Enrollment 75 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov